Selective inhibition of NADPH-oxidase isoforms as a therapeutic strategy in hypertension

Miller, A. A. , Drummond, G. R. and Sobey, C. G. (2005) Selective inhibition of NADPH-oxidase isoforms as a therapeutic strategy in hypertension. Drug Discovery Today: Therapeutic Strategies, 2(3), pp. 187-192. (doi: 10.1016/j.ddstr.2005.08.002)

Full text not currently available from Enlighten.

Abstract

Hypertension is a major public health challenge because of its high frequency and associated cardiovascular risk. Accumulating evidence suggests that reactive oxygen species derived from NADPH-oxidase play a pivotal role in vascular damage associated with hypertension. The clinical benefits of three of the most prescribed classes of cardiovascular drugs might all indirectly involve inhibition of NADPH-oxidase. Thus, development of inhibitors of vascular isoforms of NADPH-oxidase could have substantial benefit in the treatment of hypertension.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Miller, Dr Alyson
Authors: Miller, A. A., Drummond, G. R., and Sobey, C. G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Drug Discovery Today: Therapeutic Strategies
Publisher:Elsevier
ISSN:1740-6773
ISSN (Online):1740-6773
Published Online:29 September 2005

University Staff: Request a correction | Enlighten Editors: Update this record